Mitomycins.
Verweij
J
J
Department of Medical Oncology, Rotterdam Cancer Institute/Daniel Den Hoed Kliniek, Rotterdam, The Netherlands.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015687:Cell Hypoxia / Q000187:drug effects; D019008:Drug Resistance, Neoplasm; D004359:Drug Therapy, Combination; D006801:Humans; D016685:Mitomycin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008937:Mitomycins / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D010084:Oxidation-Reduction
D000903:Antibiotics, Antineoplastic; D008937:Mitomycins; D016685:Mitomycin